ASH 2021 | Highlights in multiple myeloma from ASH 2021: cilta-cel, bispecific antibodies & disease biology
Sundar Jagannath, MD, Tisch Cancer Institute at Mount Sinai, New York, NY, shares the most exciting updates in multiple myeloma presented at the ASH 2021 annual meeting. To begin with, the CARTITUDE-1 clinical trial evaluating ciltacabtagene autoleucel in patients with relapsed/refractory (R/R) multiple myeloma (NCT03548207) reported unprecedented response rates (RR), progression-free survival (PFS) and overall survival (OS) data. In addition, experts presented promising data on bispecific antibodies such as talquetamab and cevostamab, as well as on the combination of talquetamab and daratumumab in R/R multiple myeloma (TRIMM-2; NCT04108195). Dr Jagannath also highlights Dr Mouhieddine’s talk on the outcomes and management of patients with R/R myeloma who progress on bispecific antibodies. Finally, Dr Jagannath comments on our understanding of the biology of multiple myeloma and multiple myeloma precursor diseases. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
